ArticleBioorganic & medicinal chemistry letters2007
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.
Article in Bioorganic & medicinal chemistry letters, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- From Plant to Chemistry: Sources of Active Opioid Antinociceptive Principles for Medicinal Chemistry and Drug Design.Molecules (Basel, Switzerland) · 2023Review
- Solving an Old Puzzle: Elucidation and Evaluation of the Binding Mode of Salvinorin A at the Kappa Opioid Receptor.Molecules (Basel, Switzerland) · 2023Article
- Therapeutic Potential of Salvinorin A and Its Analogues in Various Neurological Disorders.Translational perioperative and pain medicine · 2022Article
- A review of salvinorin analogs and their kappa-opioid receptor activity.Bioorganic & medicinal chemistry letters · 2018Review
- Modular Approach to pseudo-Neoclerodanes as Designer κ-Opioid Ligands.Organic letters · 2017Article
- A theoretical biogenesis overview of diterpenes isolated from Salvia microphylla.Journal of molecular modeling · 2015Article
- Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A.Journal of natural products · 2014Article
- Stilbenes as κ-selective, non-nitrogenous opioid receptor antagonists.Journal of natural products · 2014Article
- Semisynthetic neoclerodanes as kappa opioid receptor probes.Bioorganic & medicinal chemistry · 2012Article
- Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.Pharmacological reviews · 2011Review
- Chemical methods for the synthesis and modification of neoclerodane diterpenes.Bioorganic & medicinal chemistry letters · 2009Review
- Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources.Pharmacology & therapeutics · 2009Review
- Salvinorin A analogs as probes in opioid pharmacology.Chemical reviews · 2008Review
- Synthesis of deacetyl-1,10-didehydrosalvinorin G.Tetrahedron letters · 2008Article
- Short synthesis of a novel class of salvinorin A analogs with hemiacetalic structure.Tetrahedron letters · 2008Article
- Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.Bioorganic & medicinal chemistry · 2008Article
- Metabolic changes in the rodent brain after acute administration of salvinorin A.Molecular imaging and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Modification of the C-1 ketone of salvinorin A (2a) produces analogues with opioid antagonist properties. Of particular significance is the finding that 1-deoxo-1,10-dehydrosalvinorin A (11a) is a moderately potent antagonist at all three opioid receptor subtypes, and that herkinorin (2b), a mu agonist, is converted to a weak antagonist by removal of the C-1 ketone (3b and 11b). These observations suggest that the ketone of 2b is a key structural feature responsible for mu agonist activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.